Paeds SAQs · endocrinology-diabetes-and-growth
Hypoglycaemia in diabetes — formative SAQs
Formative SAQs on recognising and classifying hypoglycaemia in children and adolescents with diabetes, explaining counter-regulatory failure and impaired awareness, delivering the rule of 15 and severe-event rescue, and preventing recurrence with continuous glucose monitoring and hybrid closed-loop therapy.
On this page & tools
Target exams
SAQ 1 — The severe hypoglycaemic seizure (10 marks)
A 14-year-old girl with type 1 diabetes on a hybrid closed-loop system is found having a generalised seizure at 6 am. Her father gives intramuscular glucagon and calls an ambulance. On arrival she is post-ictal with a sensor glucose of 1.7 mmol/L. (a) Outline your immediate assessment and management. (b) Classify the event by ISPAD/ADA severity. (c) Explain why her counter-regulation failed and why she did not wake. (d) Outline the prevention plan. [1] [11]
Immediate assessment and management
A seizing or post-ictal child with type 1 diabetes holds the diagnosis in her history: this is severe hypoglycaemia until proven otherwise. Secure the airway in the recovery position, give oxygen if needed, and confirm with a sensor or point-of-care glucose — which here reads 1.7 mmol/L, confirming a Level 2 biochemical event complicated by a Level 3 (severe) functional state. Her father has already given intramuscular glucagon, which is the correct community rescue drug and typically works within ten to fifteen minutes; if she had not responded, intravenous dextrose at 0.2 to 0.3 grams per kilogram would be the next step. Once she is awake and can swallow safely, follow with oral complex carbohydrate and protein, because the glucagon effect is transient and the residual insulin will continue to act. [1] [11]
Severity classification
By the ISPAD and ADA framework this is a Level 3 severe event, because the definition of severe depends on functional state rather than the glucose value: any hypoglycaemia associated with altered consciousness that requires another person to administer treatment is severe, regardless of the number. The biochemical value of 1.7 mmol/L additionally meets the Level 2 (clinically important, below 3.0) criterion. The distinction matters because a Level 3 event carries the highest recurrence risk and mandates a structured prevention review rather than a discharge on incremental adjustment. [1]
Why counter-regulation failed
In type 1 diabetes the three-tier defence fails in order. The first tier — falling endogenous insulin — is lost outright, because her insulin is delivered by a pump and there is no insulin secretion to switch off as glucose falls. The second tier, the glucagon response, is blunted by the loss of the intra-islet insulin signal. The third tier, the adrenaline response, is attenuated by any recent hypoglycaemia through hypoglycaemia-associated autonomic failure, which lowers the glucose threshold at which symptoms appear and can silence the autonomic warning altogether. She did not wake because impaired awareness removed the tremor and sweating that would normally have roused her, leaving the neuroglycopenic wave — seizure — as the first symptom. [2] [8]
The prevention plan
Begin with the continuous glucose monitoring download, which will reveal the asymptomatic nocturnal burden and the time below range. Run two to three weeks of strict hypoglycaemia avoidance — raising overnight targets, reducing the basal if the trace runs low, and treating every low aggressively — to restore the adrenaline warning and break the HAAF cycle. Ensure the hybrid closed-loop algorithm is tuned and that the pump is reducing basal appropriately as glucose falls, and rehearse the glucagon plan with the family and school. The DCCT trade-off means lowering HbA1c and protecting the brain must be reconciled, not traded against each other; modern registry data show they can be. [4] [1]
SAQ 2 — Impaired awareness in an eight-year-old (10 marks)
An eight-year-old boy with a three-year history of type 1 diabetes has had three severe hypoglycaemic events in six months. His mother reports he no longer complains of his usual "shaky" symptoms. HbA1c is 58 mmol/mol. (a) Define impaired awareness of hypoglycaemia and estimate its prevalence. (b) Explain the mechanism linking it to recurrent severe events. (c) Outline a structured management plan. [1] [8]
Definition and prevalence
Impaired awareness of hypoglycaemia is the loss of the autonomic warning — the tremor, sweating and palpitations that normally precede neuroglycopenia — so the first symptom the child experiences is confusion or collapse itself. It is common: a population-based study found it affects around one in four children and adolescents with type 1 diabetes, and it is the single strongest predictor of a future severe event. The family report of lost "shaky" symptoms is the clinical clue, and the three severe events in six months confirm the high-risk pattern. [8] [1]
Mechanism
The mechanism is hypoglycaemia-associated autonomic failure. Each hypoglycaemic event attenuates the sympathoadrenal response, which lowers the glucose threshold at which autonomic symptoms appear; as the threshold falls below the neuroglycopenic threshold, the warning is lost and the child progresses directly to confusion or seizure. This is why hypoglycaemia begets hypoglycaemia: one event weakens the warning, so the next event is silent, so the next event is more severe. The boy's three events in six months are the engine of his own loss of awareness, and the cycle will continue unless it is deliberately broken. [2] [8]
Structured management plan
Confirm the burden with a continuous glucose monitoring download, which typically exposes a far greater load of asymptomatic hypoglycaemia than the family realised. The highest-yield first step is two to three weeks of strict hypoglycaemia avoidance — raising glucose targets, reducing insulin, and treating every low aggressively — which restores the adrenaline response and the symptomatic warning. Layer on technology: continuous glucose monitoring with alarms, and hybrid closed-loop delivery where available, to provide the automated defence that his lost first tier cannot. Adjust the insulin regimen — reduce rather than omit after events, fix any mismatched basal rate, and avoid stacked boluses — and screen for co-morbidity (coeliac, adrenal insufficiency, thyroid) if the events cluster without a regimen cause. The intranasal glucagon option gives the family and school a rescue tool that does not require injection. [1] [11]
References
- [1]Abraham MB, Karges B, Dovc K, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Assessment and management of hypoglycemia in children and adolescents with diabetes Pediatr Diabetes, 2022.PMID 36537534
- [2]McCrimmon RJ, Sherwin RS. Hypoglycemia in type 1 diabetes Diabetes, 2010.PMID 20876723
- [4]The Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med, 1993.PMID 8366922
- [8]Ly TT, Gallego PH, Davis EA, Jones TW. Impaired awareness of hypoglycemia in a population-based sample of children and adolescents with type 1 diabetes Diabetes Care, 2009.PMID 19587370
- [11]Pontiroli AE, Tagliabue E. Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis Acta Diabetol, 2020.PMID 32025860